

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 October 2005 (27.10.2005)

PCT

(10) International Publication Number  
**WO 2005/100367 A1**

(51) International Patent Classification<sup>7</sup>: C07D 501/00,  
A61K 31/545

(74) Common Representative: RANBAXY LABORATO-  
RIES LIMITED; c/o DESHMUKH, Jay R., 600 College  
Road East, Suite 2100, Princeton, NJ 08540 (US).

(21) International Application Number:  
PCT/IB2005/000978

(22) International Filing Date: 13 April 2005 (13.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
708/Del/2004 13 April 2004 (13.04.2004) IN

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW.

(71) Applicant (for all designated States except US): RAN-  
BAXY LABORATORIES LIMITED [IN/IN]; 19, Nehru  
Place, New Delhi 110019, Delhi (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KUMAR, Yatendra  
[IN/IN]; U-26/5, Phase - III, DLF Qutab Enclave, Gurgaon  
122002, Haryana (IN). PRASAD, Mohan [IN/IN]; House  
No. P-3/3, Phase - II, DLF Qutab Enclave, Gurgaon  
122001, Haryana (IN). SINGH, Kaptan [IN/IN]; Flat  
No. B-02, Saket Enclave, Rajendra Nagar, Sahibabad,  
Ghaziabad 201005, Uttar Pradesh (IN). PRASAD, Ashok  
[IN/IN]; 147/9, Dr. Gupta's Flats., Kishangarh, Vasant  
Kunj, New Delhi 110070, Delhi (IN). RICHHARIYA,  
Santosh [IN/IN]; House No. 26, Ganesh Ward, Bina  
District, Sagar 470002, Madhya Pradesh (IN).


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: INTERMEDIATES USEFUL IN THE SYNTHESIS OF 3-(2-SUBSTITUTED VINYL) CEPHALOSPORINS




(57) Abstract: The present invention relates to crystalline intermediates useful in the synthesis of 3-(2-substituted vinyl) cephalosporins and processes for their preparation. In particular, the present invention relates to crystalline ylides of Formula I, processes for their preparation, and their use as an intermediate in the preparation of 3-(2-substituted vinyl) cephalosporins.

## INTERMEDIATES USEFUL IN THE SYNTHESIS OF 3-(2-SUBSTITUTED VINYL) CEPHALOSPORINS

### Field of the Invention

5        The present invention relates to crystalline intermediates useful in the synthesis of 3-(2-substituted vinyl) cephalosporins and processes for their preparation. In particular, the present invention relates to crystalline ylides of Formula I, processes for their preparation, and their use as an intermediate in the preparation of 3-(2-substituted vinyl) cephalosporins.



10        **FORMULA I**

### Background of the Invention

15        Cephalosporin antibiotics belonging to the class of 3-(2-substituted vinyl) cephalosporins have a very broad spectrum of antimicrobial activity. Cefditoren pivoxil, which belongs to this class, is highly active not only against a variety of gram-positive and gram-negative bacteria but also against some resistant strains of bacteria (see, e.g., European Patent No. 175,610).

20        European Patent No. 175,610 describes a process for preparing Cefditoren and its pharmaceutically acceptable salts and esters. The process described is non-selective and gives more than 20% of the unwanted E-isomer, which is then separated by means of column chromatography. The yield of cefditoren or its sodium salt or its pivaloxymethyl ester is reported to be very low.

25        U.S. Patent No. 6,288,223 describes a process for the selective preparation of the Z-isomer of 3-(2-substituted vinyl) cephalosporins. In this process, reaction conditions as well as solvent system are selected in such a manner that during formation of the vinyl group, selectively the Z-isomer is obtained without formation of E-isomer. The process, however, still generates about 4 to 5% of unwanted E-isomer, which needs to be separated in order to get the desired purity of the finished product. The process uses lower

temperature of about  $-50$  to  $5^{\circ}\text{C}$  when the vinyl group is formed by reaction between an ylide and an aldehyde. Stringent conditions are adopted for deprotection of the protected amino and carboxyl functionalities. The process isolates every intermediate followed by its purification and therefore is very time consuming. It gives a reduced yield of


5 Cefditoren pivoxil.

U.S. Patent No. 5,616,703 describes a process for separating cephalosporin isomers by forming amine salts. The process described therein produces the intermediates in which the unwanted E isomer is more than 20%, which is then depleted by forming amine salts. In this process the yield of the intermediate is reduced and the unwanted E-isomer, after separation, is removed from the process.

Our pending PCT patent application WO 2005/016936 describes a process for selective preparation of Z-isomer of cefditoren or pharmaceutically acceptable salts and esters thereof. The process selectively prepares Z-isomer of cefditoren pivoxil having less than 1% of the E-isomer.

# 15 Summary of the Invention

The present inventors have surprisingly found that while preparing cefditoren pivoxil by processes described in co-pending PCT patent application WO 2005/016936, they are able to modify the reaction conditions and isolate as a crystalline solid the ylide of Formula I.




20

**FORMULA I**

In Formula I, R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt.  $R_1$  and  $R_2$  are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally a substituted amino acid residue or a group of Formula A.


25

3

**FORMULA A**


In Formula A,  $R_4$  is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more  
 5 heteroatoms or halo and Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4, and  $R_5$  is selected from  $C_1$  to  $C_7$  straight or branch chain alkyl, alkenyl, alkynyl or  $C_6$  to  $C_{10}$  cycloalkyl, aryl or aralkyl.

This crystalline solid of Formula I, when used as an intermediate in the synthesis  
 10 of cefditoren pivoxil, can lead to a significant reduction in the consumption of 4-methylthiazole-5-carboxaldehyde of Formula II.


**FORMULA II**

In Formula II,  $R_3$  is 4-methylthiazole-5-yl, which is also an intermediate. This  
 15 may advantageously result in significant improvement of process economics as some of the prior art processes reported use of about 6 to 25 moles of 4-methylthiazole-5-carboxaldehyde per mole of the ylide of Formula I. The present inventors have found that this consumption can be reduced to 1.0 to 2.0 moles of 4-methylthiazole-5-carboxaldehyde per mole of ylide of Formula I when the ylide is isolated from the reaction mixture as a crystalline solid.

20 Thus, in one general aspect there is provided a crystalline ylide of Formula I:

**FORMULA I**


In Formula I, R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt, and R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A, n is an integer 2, 3 or 4, and R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl.



**FORMULA A**

In Formula A, R<sub>4</sub> is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is absent or oxygen or sulphur.

In another general aspect there is provided a crystalline ylide of Formula I.




**FORMULA I**


In Formula I, R is diphenylmethyl, one of the R<sub>1</sub> and R<sub>2</sub> is hydrogen and other is phenylacetamido group, Y is absent, R<sub>5</sub> is phenyl, and n is an integer having a value of 3.

Embodiments of the crystalline ylide may include a powdered X-Ray Diffraction pattern depicted in Figure I.

In another general aspect there is provided a process for the preparation of a crystalline ylide of Formula I.

**FORMULA I**


In Formula I, R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt, and R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A, n is an integer 2, 3 or 4, and R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl.

**FORMULA A**

In Formula A, R<sub>4</sub> is an optionally substituted lower alkyl wherein the substituents groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is absent or oxygen or sulphur.

The process includes the steps of


- a) treating a compound of Formula III

**FORMULA III**

wherein,

6

R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt, X is chloro or bromo, and R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,



5

**FORMULA A**

wherein R<sub>4</sub> is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, and heterocyclic containing one or more heteroatoms or halo,

10

with a compound of Formula IV,


**FORMULA IV**

wherein,

Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4 and R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl;

15

b) optionally isolating the product of Formula V,

**FORMULA V**

20

wherein R, R<sub>1</sub>, R<sub>2</sub>, Y, R<sub>5</sub>, X and n are as defined above;

c) treating the product of step a) or b) with a base; and


d) isolating the crystalline ylide of Formula I from the reaction mass.

Embodiments of the process may include one or more of the following features.

For example, the compound of Formula IV may be selected from trimethylphosphine, triethylphosphine, tributylphosphine, triphenylphosphine, triethyl phosphite, triphenylphosphite, triethylorthophosphite or triphenylorthophosphite.

The base may be selected from an inorganic or an organic base. The base may be selected from sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, aluminium hydroxide, sodium hydride, potassium hydride, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium t-butoxide, sodium ethoxide, triethylamine, dicyclohexylamine or diphenylamine.

In another general aspect there is provided a process for the preparation of a compound of Formula VI.



FORMULA VI

wherein,

R is hydrogen, esterified residue or a metal cation capable of forming a salt,


R<sub>3</sub> is hydrogen, halo, substituted C<sub>1-8</sub> alkyl, aryl, aralkyl, substituted heterocyclic residue containing one or more heteroatoms selected from nitrogen, oxygen, sulphur; or SR<sub>6</sub>

wherein R<sub>6</sub> is straight or branched chain C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkenyl, aryl, aralkyl, substituted aralkyl, or a heterocyclic residue,

R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, amino protecting group or combine together to form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,




8

**FORMULA A**

wherein  $R_4$  is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo,


wherein the process includes the steps of

- a) reacting the crystalline ylide of Formula I,

**FORMULA I**


wherein,

$R$  is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt,  $R_1$  and  $R_2$  are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,  $n$  is an integer 2, 3 or 4, and  $R_5$  is selected from  $C_1$  to  $C_7$  straight or branch chain alkyl, alkenyl, alkynyl or  $C_6$  to  $C_{10}$  cycloalkyl, aryl or aralkyl,

**FORMULA A**

wherein  $R_4$  is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is absent or oxygen or sulphur,

with a compound of Formula II or a suitable chemical equivalent thereof in an organic solvent at a temperature of about  $-50$  to  $35^\circ\text{C}$ ,




### FORMULA II

wherein  $R_3$  is hydrogen, halo, substituted  $\text{C}_{1-8}$  alkyl, aryl, aralkyl, substituted heterocyclic residue containing one or more heteroatoms selected from nitrogen, oxygen, sulphur; or  $\text{SR}_6$  wherein  $R_6$  is straight or branched chain  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-3}$  alkenyl, aryl, aralkyl, substituted aralkyl or a heterocyclic residue; and

b) isolating the compound of Formula VI from the reaction mass.

In another general aspect there is provided a process that includes using the crystalline ylides above for the preparation of 3-(2-substituted vinyl) cephalosporin.


Embodiments of the process may include one or more of the following features. For example, the 3-(2-substituted vinyl) cephalosporin may be cefditoren of Formula VII or pharmaceutically acceptable salts and esters thereof.




### FORMULA VII

The 3-(2-substituted vinyl) cephalosporin may be cefdinir of Formula VIII or pharmaceutically acceptable salts and esters thereof.

10

**FORMULA VIII**


The 3-(2-substituted vinyl) cephalosporin may be cefixime of Formula IX or pharmaceutically acceptable salts and esters thereof.



5

**FORMULA IX**

The 3-(2-substituted vinyl) cephalosporin may be cefprozil of Formula X or pharmaceutically acceptable salts and esters thereof.



10


**FORMULA X**

Brief Description of the Drawings


Figure 1 is a powdered X-Ray Diffraction pattern of a crystalline ylide.

Detailed Description of the Invention

5 A first aspect of the present invention provides crystalline ylides of Formula I.

**FORMULA I**


10 In Formula I, R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt. R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A.

**FORMULA A**

15 In Formula A, R<sub>4</sub> is an optionally substituted lower alkyl wherein the substituents groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4, and R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl.


A second aspect of the present invention provides a crystalline ylide of Formula I.

12

**FORMULA I**


In Formula I, R is diphenylmethyl and one of the  $R_1$  and  $R_2$  is hydrogen and the other is a phenylacetamido group; Y is absent;  $R_5$  is phenyl and n is integer having value 3 (herein  
5 onwards referred to as GCLH-ylide) having a powder X-Ray Diffraction pattern depicted in Figure I as shown in the accompanied drawings.

A third aspect of the present invention provides a process for preparation of crystalline ylides of Formula I.

**FORMULA I**

10

In Formula I, R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt and  $R_1$  and  $R_2$  are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A.

**FORMULA A**


15

In Formula A,  $R_4$  is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4, and  $R_5$

13


is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl. The process includes the steps of

a) treating a compound of Formula III



FORMULA III

wherein R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt; X is chloro or bromo; and R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,



FORMULA A

wherein R<sub>4</sub> is a optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo,

with a compound of Formula IV,




FORMULA IV

wherein Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4, and R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl;

b) optionally isolating the product of Formula V,

14



FORMULA V

wherein R, R<sub>1</sub>, R<sub>2</sub>, Y, R<sub>5</sub>, X and n are as defined above;

c) treating the product of step a) or b) with a base; and

5 d) isolating the crystalline ylide of Formula I from the reaction mass.

The compound or compounds of Formula III are treated with alkali or alkaline earth metal iodide or bromide and a phosphorous containing compound of Formula III in an organic solvent at a temperature of -10 to 50°C.

10 The alkali or alkaline earth metal iodide or bromide can be selected from sodium iodide, potassium iodide, sodium bromide, potassium bromide and such similar metal iodides or bromides.

The compound of Formula IV, wherein Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4, and R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl, can be selected from trimethylphosphine, triethylphosphine, tributylphosphine, triphenylphosphine, triethyl phosphite, triphenylphosphite, triethylorthophosphite or triphenylorthophosphite.


20 The organic solvent can be one or more of chlorinated hydrocarbons such as methylene chloride, chloroform, ethylene chloride or ethylene bromide; polar aprotic solvents such as dimethylformamide, dimethylacetamide or dimethylsulphoxide; ethers such as tetrahydrofuran, diisopropyl ether, 1,4-dioxane or diethyl ether; ketones such as acetone, methyl isobutyl ketone, methyl ethyl ketone; esters such as ethyl acetate, methyl acetate, ethyl formate, methyl formate, isopropyl acetate, n-butyl acetate, isobutyl acetate and n-propyl acetate; and lower alcohols such as methanol, ethanol, propanol, isopropanol, butanol or mixtures thereof.

25 After completion of the reaction, the compound or compounds of Formula V can be isolated from the reaction mass by suitable aqueous workup, however, the reaction

mass can, as such, be taken in the next step. The reaction mass is treated with a base at a temperature between -20 to 50°C. It is also possible to cool the organic layer obtained in step a) to -5 to 25°C and slowly add a solution of base in water or suitable organic solvent over a period of 15 minutes to 1 hour by maintaining the temperature. Ylides of Formula I start separating out from the reaction mass as a crystalline solid. After complete precipitation of the crystalline product it is filtered and optionally dried under vacuum to get an almost quantitative yield.

The base used in this step can be an inorganic compound such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, aluminium hydroxide, sodium hydride, potassium hydride, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate; one or more organic salts such as sodium methoxide, potassium t-butoxide, sodium ethoxide; or organic ammonium compounds such as triethylamine, dicyclohexylamine or diphenylamine. For the practical utility a solution of base can be made in a suitable solvent such as water.

A fourth aspect of the present invention provides a process for the preparation of compound of Formula VI,




**FORMULA VI**

wherein R is hydrogen, esterified residue or a metal cation capable of forming a salt; R<sub>3</sub> is hydrogen, halo, substituted C<sub>1-8</sub> alkyl, aryl, aralkyl, substituted heterocyclic residue containing one or more heteroatoms selected from nitrogen, oxygen, sulphur; or SR<sub>6</sub> wherein R<sub>6</sub> is straight or branched chain C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkenyl, aryl, aralkyl, substituted aralkyl, or a heterocyclic residue; and R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, amino protecting group or combine together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,




16


**FORMULA A**

wherein  $R_4$  is an optionally substituted lower alkyl wherein the substituents groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo. The process includes the steps of

a) reacting the crystalline ylide of Formula I,

**FORMULA I**


wherein, R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt and  $R_1$  and  $R_2$  are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,

**FORMULA A**

wherein  $R_4$  is an optionally substituted lower alkyl wherein the substituents groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4,

and R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl,

with a compound of Formula II or a suitable chemical equivalent thereof,



5

## FORMULA II

wherein R<sub>3</sub> is hydrogen, halo, substituted C<sub>1-8</sub> alkyl, aryl, aralkyl, substituted heterocyclic residue containing one or more heteroatoms selected from nitrogen, oxygen, sulphur; or SR<sub>6</sub> wherein R<sub>6</sub> is straight or branched chain C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkenyl, aryl, aralkyl, substituted aralkyl or a heterocyclic residue in an organic solvent at a temperature of about -50 to 35°C; and

10

b) isolating the compound of Formula VI from the reaction mass.

The compound of Formula I is treated with a compound of Formula II or a suitable chemical equivalent thereof, wherein R<sub>3</sub> is as defined above, in the presence of an organic solvent at a temperature of about -50 to 35°C. The suitable chemical equivalents include orthoesters, orthoformates, and polymeric forms of compound of Formula II. After completion of the reaction, it is quenched by addition of water followed by washing of the organic layer with sodium bisulphite solution to eliminate aldehydic and related impurities generated during reaction. The compound of Formula VI can then be isolated from the organic layer by suitable methods of isolation, which include evaporation of the organic solvent to get the product, precipitation of the product from the organic solvent by addition of anti-solvent, and the like.

15

20


The organic solvent can be one or more of chlorinated hydrocarbons such as chloroform or methylene chloride; lower alkanols such as methanol, ethanol, n-propanol, isopropanol and n-butanol; ethers such as tetrahydrofuran, diethyl ether, 1,4-dioxane; esters such as ethyl acetate, n-butyl acetate, isopropyl acetate, etc.; or ketones such as acetone, ethyl methyl ketone or mixtures thereof. A chlorinated hydrocarbon containing a lower alkanol is a preferred solvent mixture.

25


A fifth aspect of the present invention provides use of crystalline ylides of Formula I as intermediates in the synthesis of 3-(2-substituted vinyl) cephalosporin commercially

used as antimicrobials for the treatment of infectious diseases caused by gram positive, gram negative, and resistant strains of bacteria.


Examples of 3-(2-substituted vinyl) cephalosporins include cefditoren of Formula VII, cefdinir of Formula VIII, cefixime of Formula IX, cefprozil of Formula X or  
5 pharmaceutically acceptable salts and esters thereof.



FORMULA VII




FORMULA VIII



FORMULA IX

19

**FORMULA X**

While the present inventions have been described in terms of their specific  
embodiments, certain modifications and equivalents will be apparent to those skilled in the  
art and are intended to be included within the scope of the present inventions.

**EXAMPLES**

Example 1: Preparation of 1,1-diphenylmethyl 7-(phenylacetamido)-3-  
[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate

To a stirred mixture of dimethylformamide (20 ml) and methylene chloride (10 ml)  
at ambient temperature was added 4-diphenylmethyl 7-phenylacetamido-3-chloromethyl-  
3-cephem-4-carboxylate (10 g) followed by addition of triphenylphosphine (0.51 g) and  
sodium bromide (0.23 g). This mixture was stirred for 2 to 3 hours and cooled to 10 to  
15°C, followed by addition of sodium carbonate (16 ml, 10% aqueous solution). The  
temperature was raised to 20 to 25°C and stirring was continued for 1.5 hours. The title  
compound was filtered as crystalline solid (16 g) under suction.

Example 2: Preparation of Cefditoren Acid Sodium Salt

**Step A) Preparation of 7-Amino-3-[2-(4-Methylthiazol-5-yl)Vinyl]-3-Cepheme-4-  
Carboxylic Acid**

1,1-diphenylmethyl 7-(phenylacetamido)-3-[(triphenylphosphoranylidene)methyl]-  
3-cephem-4-carboxylate (16 g) was mixed with methylene chloride (120 ml) and 1-  
propanol (40 ml) followed by addition of 4-methylthiazol-5-carboxaldehyde (3 g). The  
resultant heterogeneous mixture was stirred at 20 to 25°C for 20 to 22 hours. Progress of  
the reaction was monitored by HPLC. After completion, the reaction mixture was  
sequentially washed with 3% sodium bisulfite (100 ml) and water (100 ml). The organic  
layer was concentrated under reduced pressure to get an oily residue of 1,1,-

diphenylmethyl 7-(phenylacetamido)-3-[2-(4-methylthiazol-5-yl)vinyl]-3-cephem-4-carboxylate. To this oily residue phenol (60 ml) was added to the residue to get a clear solution. This solution was stirred at 40 to 50°C for 10 to 12 hours and n-butyl acetate (150 ml) was added to the reaction mass followed by cooling to 5 to 10°C. The organic  
5 portion was extracted with sodium bicarbonate solution (0.17 Molar, 2 x 150 ml). The aqueous layer was washed with n-butyl acetate (2 x 150 ml) to remove traces of phenol. To the clear aqueous layer was added Pen-G amidase (8 g wet) at 20 to 25°C. The pH of the reaction was intermittently adjusted to 7.5 to 7.7 by slow addition of 5% sodium carbonate solution. After completion of the reaction, the enzyme was filtered and washed  
10 with de-ionized water. The filtrate was treated with activated carbon and then filtered at 30–35°C. The filtrate was cooled to 20–25°C and to it was added dilute HCl (2 Molar) to adjust the pH to 3.0 to 3.5 in order to effect complete precipitation of the title compound. The product was filtered and sequentially washed with water and acetone and finally dried under vacuum to get 5.5 g of off-white title compound.


#### 15 Step B) Preparation of cefditoren acid sodium salt

A suspension of product obtained in Step A) (5.0 g, 15.4 mmol) and 2-methoxyimino-2-(2-amino thiazol-4-yl)acetic acid, S-2-benzothiazole ester (6.7 g, 18.6 mmol) in aqueous tetrahydrofuran (60 ml) was stirred at 0 to 5°C. Triethylamine (2.3 ml) was added slowly at 0–5°C over 15 to 20 minutes. The mixture was stirred at 0–5°C for 2–3 hours. The  
20 reaction was quenched by addition of dichloromethane followed by layer separation. The aqueous layer was diluted with acetone to 50 ml. Sodium 2-ethylhexanoate (3.3 g, 19.8 mmol) was added to the aqueous acetone solution at 20–25°C. After stirring the mixture for sufficient time for crystallization of sodium salt of Cefditoren, acetone (50 ml) was slowly added to the reaction mass in order to complete the crystallization. The crystallized  
25 product was filtered under suction and washed with acetone (2 x 10 ml). The product was vacuum dried to get 6.5 g of off-white title compound (Yield = 75%).

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention.


**We claim:**

- 1 1. A crystalline ylide of Formula I,

**FORMULA I**

2  
3  
4 wherein,


5 R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt, and  
6 R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together  
7 form a divalent amino protecting group, optionally substituted amino acid residue or a  
8 group of Formula A,

**FORMULA A**

9  
10  
11 wherein,

12 R<sub>4</sub> is an optionally substituted lower alkyl wherein the substituent groups are selected from  
13 carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is  
14 absent or oxygen or sulphur,  
15 n is an integer 2, 3 or 4, and  
16 R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub>  
17 cycloalkyl, aryl or aralkyl.

1 2. A crystalline ylide of Formula I,



2

3

**FORMULA I**

4 wherein,

5 R is diphenylmethyl,

6 one of the R<sub>1</sub> and R<sub>2</sub> is hydrogen and other is phenylacetamido group,


7 Y is absent,

8 R<sub>5</sub> is phenyl, and

9 n is an integer having a value of 3.

1 3. The crystalline ylide of claim 2 having a powdered X-Ray Diffraction pattern depicted  
2 in Figure I.

1 4. A process for the preparation of a crystalline ylide of Formula I,



2

3


**FORMULA I**

4 wherein,

5 R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt, and

6 R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together  
7 form a divalent amino protecting group, optionally substituted amino acid residue or a  
8 group of Formula A,

23



9

10

**FORMULA A**


11 wherein  $R_4$  is an optionally substituted lower alkyl wherein the substituents groups are  
 12 selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or  
 13 halo and Y is absent or oxygen or sulphur,

14 n is an integer 2, 3 or 4, and

15  $R_5$  is selected from  $C_1$  to  $C_7$  straight or branch chain alkyl, alkenyl, alkynyl or  $C_6$  to  $C_{10}$   
 16 cycloalkyl, aryl or aralkyl,

17 wherein the process comprises the steps of

18 a) treating a compound of Formula III



19

20

**FORMULA III**

21

wherein,


22

23

24

25

R is a hydrogen atom, esterifying residue or a metal cation capable of forming a  
 salt, X is chloro or bromo, and  $R_1$  and  $R_2$  are independently hydrogen, monovalent  
 amino protecting group or together form a divalent amino protecting group,  
 optionally substituted amino acid residue or a group of Formula A,



26



27 **FORMULA A**

28 wherein  $R_4$  is an optionally substituted lower alkyl wherein the substituent groups  
29 are selected from carboxyl, hydroxy, aryl, and heterocyclic containing one or more  
30 heteroatoms or halo,

31 with a compound of Formula IV,




33 **FORMULA IV**

34 wherein,

35 Y is absent or oxygen or sulphur, n is an integer 2, 3 or 4 and  $R_5$  is selected from  
36  $C_1$  to  $C_7$  straight or branch chain alkyl, alkenyl, alkynyl or  $C_6$  to  $C_{10}$  cycloalkyl,  
37 aryl or aralkyl;

38 b) optionally isolating the product of Formula V,



40 **FORMULA V**

41 wherein R,  $R_1$ ,  $R_2$ , Y,  $R_5$ , X and n are as defined above;

42 c) treating the product of step a) or b) with a base; and

43 d) isolating the crystalline ylide of Formula I from the reaction mass.


1 5. The process of claim 4 wherein the compound of Formula IV is selected from  
2 trimethylphosphine, triethylphosphine, tributylphosphine, triphenylphosphine, triethyl  
3 phosphite, triphenylphosphite, triethylorthophosphite or triphenylorthophosphite.

1 6. The process of claim 4 wherein the base is selected from an inorganic or an organic  
2 base.

1 7. The process of claim 6 wherein base is selected from sodium hydroxide, potassium  
2 hydroxide, calcium hydroxide, magnesium hydroxide, aluminium hydroxide, sodium

hydride, potassium hydride, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium t-butoxide, sodium ethoxide, triethylamine, dicyclohexylamine or diphenylamine.

8. A process for the preparation of a compound of Formula VI,




FORMULA VI

wherein,

R is hydrogen, esterified residue or a metal cation capable of forming a salt,

R<sub>3</sub> is hydrogen, halo, substituted C<sub>1-8</sub> alkyl, aryl, aralkyl, substituted heterocyclic residue containing one or more heteroatoms selected from nitrogen, oxygen, sulphur; or SR<sub>6</sub> wherein R<sub>6</sub> is straight or branched chain C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkenyl, aryl, aralkyl, substituted aralkyl, or a heterocyclic residue,

R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, amino protecting group or combine together to form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,




FORMULA A

wherein R<sub>4</sub> is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo,

wherein the process comprises the steps of

26

a) reacting the crystalline ylide of Formula I,




FORMULA I

wherein,

R is a hydrogen atom, esterifying residue or a metal cation capable of forming a salt,

R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, monovalent amino protecting group or together form a divalent amino protecting group, optionally substituted amino acid residue or a group of Formula A,




FORMULA A

wherein R<sub>4</sub> is an optionally substituted lower alkyl wherein the substituent groups are selected from carboxyl, hydroxy, aryl, heterocyclic containing one or more heteroatoms or halo and Y is absent or oxygen or sulphur,

n is an integer 2, 3 or 4, and

R<sub>5</sub> is selected from C<sub>1</sub> to C<sub>7</sub> straight or branch chain alkyl, alkenyl, alkynyl or C<sub>6</sub> to C<sub>10</sub> cycloalkyl, aryl or aralkyl,

with a compound of Formula II or a suitable chemical equivalent thereof in an organic solvent at a temperature of about -50 to 35°C,




FORMULA II

wherein  $R_3$  is hydrogen, halo, substituted  $C_{1-8}$  alkyl, aryl, aralkyl, substituted, heterocyclic residue containing one or more heteroatoms selected from nitrogen, oxygen, sulphur; or  $SR_6$  wherein  $R_6$  is straight or branched chain  $C_{1-4}$  alkyl,  $C_{1-3}$  alkenyl, aryl, aralkyl, substituted aralkyl or a heterocyclic residue; and

b) isolating the compound of Formula VI from the reaction mass.


9. A process comprising using the crystalline ylide of claims 1 or 2 for the preparation of 3-(2-substituted vinyl) cephalosporin.

10. The process according to claim 9 wherein the 3-(2-substituted vinyl) cephalosporin is cefditoren of Formula VII or pharmaceutically acceptable salts and esters thereof.



FORMULA VII


11. The process according to claim 9 wherein the 3-(2-substituted vinyl) cephalosporin is cefdinir of Formula VIII or pharmaceutically acceptable salts and esters thereof.



FORMULA VIII


12. The process according to claim 9 wherein the 3-(2-substituted vinyl) cephalosporin is cefixime of Formula IX or pharmaceutically acceptable salts and esters thereof.

28



FORMULA IX

13. The process according to claim 9 wherein the 3-(2-substituted vinyl) cephalosporin is cefprozil of Formula X or pharmaceutically acceptable salts and esters thereof.



FORMULA X




FIGURE 1: XRD OF CRYSTALLINE GCLH-YLIDE

## INTERNATIONAL SEARCH REPORT

 Intern Application No  
 PCT/IB2005/000978

 A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C07D501/00 A61K 31/545

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/083692 A (HANMI PHARM. CO., LTD; LEE, GWAN SUN; CHANG, YOUNG KIL; KIM, HONG SUN;) 24 October 2002 (2002-10-24) examples	1,2
X	EP 1 016 665 A (MEIJI SEIKA KAISHA, LTD) 5 July 2000 (2000-07-05) page 10 - page 11; examples	1,2
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

23 June 2005

Date of mailing of the international search report

30/06/2005

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Menegaki, F

## INTERNATIONAL SEARCH REPORT

Intern: Application No  
PCT/IB2005/000978

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SAKAGAMI K ET AL: "SYNTHESIS AND ORAL ACTIVITY OF PIVALOYLOCYMETHYL7-Ä(Z)-2-(2-AMINOTHIAZOL-4-YL)-2-METHOXYIMINOACETAMIDOÜ-3-(Z)-(4-METHYLTHIAZOL-5-YL)VINYL-3-CEPHEM-4-CARBOXYLATE (ME1207) AND ITS RELATED COMPOUND"</p> <p>September 1991 (1991-09), CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, PAGE(S) 2433-2436 , XP009042230 ISSN: 0009-2363 examples 4,5</p> <p>-----</p>	1-13
Y	<p>EP 0 175 610 A (MEIJI SEIKA KAISHA LTD; MITSUHASHI, SUSUMU) 26 March 1986 (1986-03-26) cited in the application examples</p> <p>-----</p>	1-13



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
**PCT/IB2005/000978**

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02083692	A	24-10-2002	KR 2002080838 A	26-10-2002
			CN 1529707 A	15-09-2004
			EP 1379530 A1	14-01-2004
			JP 2005501812 T	20-01-2005
			WO 02083692 A1	24-10-2002
			US 2004132992 A1	08-07-2004
EP 1016665	A	05-07-2000	AT 221890 T	15-08-2002
			AU 731265 B2	29-03-2001
			AU 7933198 A	04-01-1999
			BR 9810313 A	19-09-2000
			CA 2294178 A1	30-12-1998
			DE 69807093 D1	12-09-2002
			DE 69807093 T2	27-03-2003
			EA 2449 B1	25-04-2002
			EP 1016665 A1	05-07-2000
			IL 133681 A	31-10-2003
			NZ 502234 A	29-06-2001
			PL 339361 A1	18-12-2000
			SK 185799 A3	11-07-2000
			US 6288223 B1	11-09-2001
			CN 1107679 C	07-05-2003
			ES 2182330 T3	01-03-2003
			HU 0002458 A2	28-02-2001
			ID 24210 A	13-07-2000
			WO 9858932 A1	30-12-1998
			PT 1016665 T	31-12-2002
			TR 200000310 T2	21-08-2000
EP 0175610	A	26-03-1986	JP 62019593 A	28-01-1987
			JP 1698887 C	28-09-1992
			JP 3064503 B	07-10-1991
			JP 61178991 A	11-08-1986
			AT 56017 T	15-09-1990
			CA 1272714 A1	14-08-1990
			CN 85106733 A ,C	14-01-1987
			DE 3579399 D1	04-10-1990
			EP 0175610 A2	26-03-1986
			ES 8704955 A1	01-07-1987
			IE 58487 B1	22-09-1993
			KR 8901196 B1	27-04-1989
			US 4839350 A	13-06-1989